PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1454740
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1454740
Structural Heart Devices Market - By Product (Heart Valve Devices, Occluders & Delivery Systems, Annuloplasty Rings), By Procedure (Replacement, Repair), By End-use (Hospitals, ASC, Cardiac Catheterization Labs) - Global Forecast, 2024 - 2032
Structural Heart Devices Market size is poised to expand at 8.8% CAGR between 2024 and 2032 due to the expanding application scope and continuous new product developments.
Beyond traditional procedures, such as valve replacements and repairs, structural heart devices are used for treating a wide range of conditions, including atrial septal defects (ASDs), patent foramen ovale (PFO), and left atrial appendage closures (LAAC). Moreover, the ongoing advancements in device technologies are leading to the development of novel materials, improved delivery systems, and enhanced imaging techniques. For instance, in March 2024, Abbott introduced the most recent version of its Navitor heart valve technology in the U.S. with several improvements over the last model. Such new product developments to offer improved efficacy, safety, and outcomes are fueling the demand for structural heart devices worldwide.
The industry is segmented into product, procedure, end-use, and region.
Based on product, the market share from the annuloplasty rings segment is projected to gain significant traction at 9.1% CAGR from 2024-2032. These rings play a vital role in surgical procedures for heart valve repair and replacement, particularly in mitral and tricuspid valve surgeries. The rising prevalence of valvular heart diseases coupled with the increasing adoption of minimally invasive surgical techniques will drive the demand for annuloplasty rings to provide structural support to the heart valves for improving their function and durability. Furthermore, advancements in ring designs, materials, and technologies are also propelling the segment growth.
With respect to end-use, the structural heart devices market from the cardiac catheterization labs segment generated considerable revenue in 2023 and is estimated to witness 9.1% growth rate through 2032. Cardiac catheterization labs are at the forefront of minimally invasive procedures for structural heart conditions, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR). The increasing prevalence of cardiovascular diseases and the preference for less invasive treatment options are fueling the demand for structural heart devices in these specialized facilities.
Given the regional landscape, the Asia Pacific structural heart devices industry is set to exhibit 9.9% CAGR from 2024-2032 driven by the rising prevalence of cardiovascular diseases, coupled with the aging population and changing lifestyles. Moreover, the improving economic conditions and increasing healthcare expenditure are facilitating the adoption of advanced cardiac procedures across the region. As a result, countries including China, India, Japan, and South Korea are becoming significant hubs for structural heart device manufacturers. Advancements in healthcare infrastructure, access to sophisticated medical technologies, and the growing number of skilled healthcare professionals are further driving the regional market expansion.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast calculations
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing burden of cardiovascular diseases
- 3.2.1.2 Technological advancements
- 3.2.1.3 Favorable reimbursement scenario
- 3.2.1.4 Rising preference for minimally invasive procedures
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Stringent regulatory policies
- 3.2.2.2 Potential complications and adverse events
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Porter's analysis
- 3.4.1 Supplier power
- 3.4.2 Buyer power
- 3.4.3 Threat of new entrants
- 3.4.4 Threat of substitutes
- 3.4.5 Industry rivalry
- 3.5 PESTEL analysis
- 3.6 Pricing analysis, 2023
- 3.7 Reimbursement scenario
- 3.8 Regulatory landscape
- 3.9 Technological landscape
- 3.10 Future market trends
- 3.11 GAP analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Heart valve devices
- 5.2.1 Surgical heart valves
- 5.2.2 Transcatheter heart valves
- 5.3 Annuloplasty rings
- 5.4 Occluders & delivery systems
- 5.5 Other products
Chapter 6 Market Estimates and Forecast, By Procedure, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Replacement procedures
- 6.2.1 Surgical aortic valve replacement (SAVR)
- 6.2.2 Transcatheter aortic valve replacement (TAVR)
- 6.2.3 Transcatheter mitral valve replacement (TMVR)
- 6.2.4 Other replacement procedures
- 6.3 Repair procedures
- 6.3.1 Left atrial appendage closure (LAAC)
- 6.3.2 Transcatheter mitral valve repair (TMVr)
- 6.3.3 Transcatheter tricuspid valve repair (TTVr)
- 6.3.4 Valvuloplasty
- 6.3.5 Other repair procedures
Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Ambulatory surgical centers
- 7.4 Cardiac catheterization labs
- 7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 AtriCure, Inc.
- 9.3 Biomerics, LLC
- 9.4 Boston Scientific Corporation
- 9.5 Braile Biomedica
- 9.6 Cryolife Inc.
- 9.7 Edwards Lifesciences Corporation
- 9.8 JenaValve Technology, Inc.
- 9.9 Lepu Medical Technology(Beijing)Co.,Ltd.
- 9.10 LivaNova PLC
- 9.11 Medtronic plc
- 9.12 NuMed Inc.
